Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours Β· Estimated delivery Aug 10 - Aug 15
De volumekorting wordt automatisch toegepast vanaf 10 vials zonder code
Key Research Features Dual-mechanism research blend angiogenic + cytoskeletal pathways BPC-157: VEGF/VEGFR2-Akt-eNOS axis and NO system modulation TB-500: actin sequestration and G-actin/F-actin polymerization balance Precision co-lyophilized 1:1 ratio minimizes preparation variability 20mg total content suited for high-throughput and extended protocols 99% HPLC-verified purity per component Lyophilized powder format Suitable for in vitro and preclinical research Batch-tested for consistency Research-grade manufacturing standards Professionally labeled and documented Storage Recommendations To maintain product stability and research integrity, BPC-157 / TB-500 should be: Stored at 20C in a tightly sealed container Reconstituted with sterile bacteriostatic water, added slowly along the vial wall with gentle swirling avoid vigorous shaking Protected from light and moisture Kept sealed until use Handled according to standard laboratory procedures Not subjected to repeated freeze-thaw cycles Toxicology and Regulatory Information BPC-157 evaluated in preclinical toxicology research models BPC-157 listed by the U.S
PMCID: PMC7447324
GS with B12 Injections and FIP Treatment Success In addition to B12 injections, FIP treatment protocols includes the use of GS-441524 antiviral drugs
Sleep Quality Enhancement Increased growth hormone pulses improve deep sleep phases, which strengthens the bodys capacity for comprehensive recovery
Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy
